The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal Fibroblasts

Background/Aim: (rMETase) degrades extracellular methionine. rMETase, or other means of restricting methionine, in combination with numerous types of chemotherapy have shown synergistic cancer-selective efficacy. AG-270, a methionine adenosyltransferase 2A (MAT2A) inhibitor, blocks intracellular conversion of methionine to S-adenosylmethionine (SAM), the central reaction of the methionine cycle. The present study aimed to evaluate the synergistic and cancer-selective efficacy of the combination of AG-270 and rMETase in a co-culture model of cancer and normal cells. Materials and Methods: HCT116 human colon-cancer cells expressing green fluorescent protein (GFP) and human Hs-27 normal fibroblasts were co-cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum in 12-well plates. Co-cultures were treated with AG-270 (6 μM and 10 µM) and rMETase (0.3 U/ml and 0.5 U/ml) alone or in combination. Cell growth and viability were assessed by phase-contrast microscopy and fluorescence imaging over 6 days. Results: Treatment with AG-270 or rMETase alone inhibited HCT116 colon-cancer cell viability in a dose-dependent manner, whereas Hs-27 normal fibroblasts remained viable on day 6 in co-culture. In contrast, the combination of AG-270 and rMETase produced a strong, synergistic reduction of the viability of both HCT116 and Hs-27 cells, accompanied by extensive morphological damage, in co-culture. GFP-expressing HCT116 colon-cancer cells were nearly eradicated by the combination treatment, as visualized by fluorescence imaging on day 6 in co-culture with Hs-27 fibroblasts. Conclusion: Dual inhibition of methionine metabolism by AG-270 and rMETase was toxic to both cancer cells and normal fibroblasts in a co-culture model which is internally controlled. In contrast, rMETase combined with numerous first-line chemotherapeutic drugs acted selectively and synergistically against cancer cells while sparing normal cells, including co-culture models. The present results suggest that AG-270 may have limited potential as an anticancer agent.

Authors

Institutions

Publication Details

Journal
Cancer Diagnosis & Prognosis
Published
2026-05-01
DOI
https://doi.org/10.21873/cdp.10559
Primary Topic
Cancer Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal Fibroblasts

Yohei Asano, KOHEI MIZUTA, YUTA MIYASHI, MICHAEL BOUVET et al.
Cancer Diagnosis & Prognosis
Cancer Research and Treatments
article

The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal Fibroblasts

Yohei Asano, KOHEI MIZUTA, YUTA MIYASHI, MICHAEL BOUVET, BYUNG MO KANG, SHUKUAN LI, ROBERT M. HOFFMAN, JINSOO KIM, QINGHONG HAN
article en

Abstract

Background/Aim: (rMETase) degrades extracellular methionine. rMETase, or other means of restricting methionine, in combination with numerous types of chemotherapy have shown synergistic cancer-selective efficacy. AG-270, a methionine adenosyltransferase 2A (MAT2A) inhibitor, blocks intracellular conversion of methionine to S-adenosylmethionine (SAM), the central reaction of the methionine cycle. The present study aimed to evaluate the synergistic and cancer-selective efficacy of the combination of AG-270 and rMETase in a co-culture model of cancer and normal cells. Materials and Methods: HCT116 human colon-cancer cells expressing green fluorescent protein (GFP) and human Hs-27 normal fibroblasts were co-cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum in 12-well plates. Co-cultures were treated with AG-270 (6 μM and 10 µM) and rMETase (0.3 U/ml and 0.5 U/ml) alone or in combination. Cell growth and viability were assessed by phase-contrast microscopy and fluorescence imaging over 6 days. Results: Treatment with AG-270 or rMETase alone inhibited HCT116 colon-cancer cell viability in a dose-dependent manner, whereas Hs-27 normal fibroblasts remained viable on day 6 in co-culture. In contrast, the combination of AG-270 and rMETase produced a strong, synergistic reduction of the viability of both HCT116 and Hs-27 cells, accompanied by extensive morphological damage, in co-culture. GFP-expressing HCT116 colon-cancer cells were nearly eradicated by the combination treatment, as visualized by fluorescence imaging on day 6 in co-culture with Hs-27 fibroblasts. Conclusion: Dual inhibition of methionine metabolism by AG-270 and rMETase was toxic to both cancer cells and normal fibroblasts in a co-culture model which is internally controlled. In contrast, rMETase combined with numerous first-line chemotherapeutic drugs acted selectively and synergistically against cancer cells while sparing normal cells, including co-culture models. The present results suggest that AG-270 may have limited potential as an anticancer agent.

Cancer Diagnosis & PrognosisVol. 6(3)
Chungnam National University (KR), University of California San Diego (US), AntiCancer (United States) (US)
Good health and well-being
Openalex Percentile: Top 12%
Cancer Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.